Bevacizumab reduces the growth rate constants of renal carcinomas: a novel algorithm suggests early discontinuation of bevacizumab resulted in a lack of survival advantage.
about
Effect of angiogenesis inhibitor bevacizumab on survival in patients with cancer: a meta-analysis of the published literature.Tumor growth rates derived from data for patients in a clinical trial correlate strongly with patient survival: a novel strategy for evaluation of clinical trial data.Other paradigms: growth rate constants and tumor burden determined using computed tomography data correlate strongly with the overall survival of patients with renal cell carcinoma.Continuing a cancer treatment despite tumor growth may be valuable: sunitinib in renal cell carcinoma as example.Analyzing the pivotal trial that compared sunitinib and IFN-α in renal cell carcinoma, using a method that assesses tumor regression and growth.Antiangiogenic therapy: impact on invasion, disease progression, and metastasis.Demystifying immunotherapy in prostate cancer: understanding current and future treatment strategies.Immunotherapy in prostate cancer: emerging strategies against a formidable foe.Estimation of renal cell carcinoma treatment effects from disease progression modelingTumor growth rate is an early indicator of antitumor drug activity in phase I clinical trialsSimplifying the complexity of resistance heterogeneity in metastasisThe VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer.Evaluation of tumor size response metrics to predict survival in oncology clinical trials.Integrating Immunotherapies in Prostate Cancer.Nab-paclitaxel in patients with metastatic melanoma.Performance of tumor growth kinetics as an imaging biomarker for response assessment in colorectal liver metastases: correlation with FDG PET.Translating new data to the daily practice in second line treatment of renal cell carcinoma: The role of tumor growth rate.Neutral evolution of drug resistant colorectal cancer cell populations is independent of their KRAS status.Current Challenges of Cancer Anti-angiogenic Therapy and the Promise of Nanotherapeutics.On the relationship between tumour growth rate and survival in non-small cell lung cancer.Mechanistic modeling quantifies the influence of tumor growth kinetics on the response to anti-angiogenic treatment.The impact of tumor burden characteristics in patients with metastatic renal cell carcinoma treated with sunitinib.mouse study identifies tumour growth kinetics as biomarkers for the outcome of anti-angiogenic treatment
P2860
Q31060162-8A696238-B51D-4ADC-B764-6C7F2B975D39Q33374219-A8EE41C3-D788-42DC-B7E6-549448874791Q33510328-EDB68D93-C8E4-477B-9BAD-FD38340D37ADQ33567889-B6B3C5D4-A0BF-4D6F-9050-346B4659E780Q35894702-5E27ECB6-E140-4C06-9F3B-617A6CB4BE25Q35966757-F752A19C-DC76-4765-9286-2D5781C82322Q36567448-E6C78C34-EEB7-42A9-8C20-D4023E3ABAA7Q36708792-37BE0028-CFC4-4AB7-B59A-BBED2F473422Q37217573-36C272D9-55B5-4943-ACFC-BB57EE078EEDQ37626194-536EA535-6B10-403E-B03F-94A9C4A3CF39Q37655188-7707F9B2-291B-48AD-98A1-FFFDC3257094Q37681171-C3919C83-AE44-4969-9CCF-49165FFFE0FEQ38178093-0352C174-ADCF-4436-B7FA-15ACAF196324Q38567067-2A3834AC-9792-4D3A-A2F6-C3F9D6FA829BQ38625186-0372E6E5-5CA7-4D30-9D6E-E8279C73AC8AQ40557514-7B4C458F-AA67-4C40-B7CA-F886D57235A9Q42365081-04B71FA3-5642-4EE9-AD2A-4BDC81C3F845Q42370649-BD4F295A-7032-4EAD-98BB-B1F4C8E809BDQ47119535-BC0B1AC9-3D7A-4ECE-B9FF-ADDC4B6AAD2FQ47151204-AE3C5EE6-7FDF-4A7A-A32A-1A3AE3E80B7EQ47228068-EEA36008-7252-410A-A3AE-2F7E31B422AAQ54640859-D05F1E21-320F-4794-826C-374F68A05D29Q58718463-612DF2CD-87CD-4D4C-B2DB-1C4D36B0CA16
P2860
Bevacizumab reduces the growth rate constants of renal carcinomas: a novel algorithm suggests early discontinuation of bevacizumab resulted in a lack of survival advantage.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Bevacizumab reduces the growth ...... a lack of survival advantage.
@ast
Bevacizumab reduces the growth ...... a lack of survival advantage.
@en
type
label
Bevacizumab reduces the growth ...... a lack of survival advantage.
@ast
Bevacizumab reduces the growth ...... a lack of survival advantage.
@en
prefLabel
Bevacizumab reduces the growth ...... a lack of survival advantage.
@ast
Bevacizumab reduces the growth ...... a lack of survival advantage.
@en
P2093
P2860
P1433
P1476
Bevacizumab reduces the growth ...... a lack of survival advantage.
@en
P2093
James Yang
Susan E Bates
Wilfred D Stein
P2860
P304
P356
10.1634/THEONCOLOGIST.2008-0016
P577
2008-09-30T00:00:00Z